BR112018003252A2 - polipeptídeos mrka, anticorpos, e usos dos mesmos - Google Patents

polipeptídeos mrka, anticorpos, e usos dos mesmos

Info

Publication number
BR112018003252A2
BR112018003252A2 BR112018003252A BR112018003252A BR112018003252A2 BR 112018003252 A2 BR112018003252 A2 BR 112018003252A2 BR 112018003252 A BR112018003252 A BR 112018003252A BR 112018003252 A BR112018003252 A BR 112018003252A BR 112018003252 A2 BR112018003252 A2 BR 112018003252A2
Authority
BR
Brazil
Prior art keywords
mrka
klebsiella
antibodies
fragments
subject
Prior art date
Application number
BR112018003252A
Other languages
English (en)
Portuguese (pt)
Inventor
Kendall Stover Charles
Chang Chew-Shun
Lin Hung-Yu
Heidbrink Thompson Jenny
Pennini Meghan
S Chowdhury Partha
Wang Qun
Rajan Saravanan
Dall'acqua William
Xiao Xiaodong
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of BR112018003252A2 publication Critical patent/BR112018003252A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112018003252A 2015-08-24 2016-08-23 polipeptídeos mrka, anticorpos, e usos dos mesmos BR112018003252A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562208975P 2015-08-24 2015-08-24
US201562238828P 2015-10-08 2015-10-08
PCT/US2016/048221 WO2017035154A1 (en) 2015-08-24 2016-08-23 Mrka polypeptides, antibodies, and uses thereof

Publications (1)

Publication Number Publication Date
BR112018003252A2 true BR112018003252A2 (pt) 2018-09-25

Family

ID=58100831

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003252A BR112018003252A2 (pt) 2015-08-24 2016-08-23 polipeptídeos mrka, anticorpos, e usos dos mesmos

Country Status (16)

Country Link
US (2) US20170073397A1 (https=)
EP (1) EP3341004A4 (https=)
JP (1) JP2018527924A (https=)
KR (1) KR20180042300A (https=)
CN (1) CN107921086A (https=)
AU (1) AU2016313653A1 (https=)
BR (1) BR112018003252A2 (https=)
CA (1) CA2995387A1 (https=)
CL (1) CL2018000357A1 (https=)
CO (1) CO2018001985A2 (https=)
HK (1) HK1252350A1 (https=)
IL (1) IL257434A (https=)
MX (1) MX2018001964A (https=)
RU (1) RU2018107056A (https=)
TW (1) TW201718626A (https=)
WO (1) WO2017035154A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
US11117956B2 (en) 2016-10-19 2021-09-14 Medimmune, Llc Anti-O1 antibodies and uses thereof
WO2018237221A1 (en) * 2017-06-23 2018-12-27 Nosocomial Vaccine Corporation IMMUNOGENIC COMPOSITIONS
CN115838430A (zh) * 2022-07-08 2023-03-24 中国人民解放军陆军军医大学 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用
CN116813725B (zh) * 2023-07-06 2025-11-04 深圳康泰生物制品股份有限公司 肺炎克雷伯菌的FimA的抗原表位肽及其应用
CN119798389A (zh) * 2024-12-12 2025-04-11 中国人民解放军军事科学院军事医学研究院 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
AU7470300A (en) * 1999-08-11 2001-03-05 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
CA2541360A1 (en) * 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
EP2489673A3 (en) * 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
WO2011100700A2 (en) * 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
US20140011691A1 (en) * 2010-10-26 2014-01-09 Arizona Board of Regents, A Body Corporate of the State of Arizona, Acting for and on Behalf of Az. Morphology and protein specific reagents as diagnostics for neurodegenerative diseases
BR112014011028B1 (pt) * 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição

Also Published As

Publication number Publication date
US20190062411A1 (en) 2019-02-28
KR20180042300A (ko) 2018-04-25
CA2995387A1 (en) 2017-03-02
EP3341004A1 (en) 2018-07-04
CO2018001985A2 (es) 2018-11-22
CL2018000357A1 (es) 2018-07-20
MX2018001964A (es) 2018-06-19
TW201718626A (zh) 2017-06-01
AU2016313653A1 (en) 2018-04-12
US20170073397A1 (en) 2017-03-16
JP2018527924A (ja) 2018-09-27
HK1252350A1 (zh) 2019-05-24
CN107921086A (zh) 2018-04-17
EP3341004A4 (en) 2019-05-15
IL257434A (en) 2018-04-30
RU2018107056A (ru) 2019-09-26
WO2017035154A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
BR112018003252A2 (pt) polipeptídeos mrka, anticorpos, e usos dos mesmos
BR112019007147A2 (pt) anticorpos anti-o1 e usos dos mesmos
JOP20200312A1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
BR112017027549A2 (pt) anticorpo para cd40
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
BR112016004324A2 (pt) anticorpos
BR112015021134A2 (pt) conjugados de fármaco e anticorpo
SG10201907215QA (en) Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
JO3739B1 (ar) روابط ctla4
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
BR112015014621A2 (pt) Anticorpos anti-h7cr
BR112019002039A2 (pt) anticorpos anti-o2 e uso dos mesmos
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
BR112018000632A8 (pt) Moléculas de anticorpo que ligam a cd79
BR112018068678A2 (pt) anticorpos anti-mica
WO2018005682A3 (en) Pd-l1-specific antibodies and methods of using the same
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
MX389103B (es) Anticuerpos contra ticagrelor y métodos de uso.
BR112019011370A2 (pt) terapia de combinação

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]